The Effects of Oral Vasopressin on Attention Control: An Eye-tracking Study
Overview
- Phase
- Not Applicable
- Intervention
- Placebo
- Conditions
- Healthy
- Sponsor
- University of Electronic Science and Technology of China
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The main aim of the present study is to investigate the effects of orally administered vasopressin (AVP) on bottom-up and top-down attentional control to socio-emotional stimuli by combining a validated saccade/antisaccade eye-tracking paradigm with a randomized between-subject placebo-controlled pharmacological trial design.
Detailed Description
Animal models and initial findings in humans suggest a role of the AVP signaling system in socio-emotional processes. Initial studies have employed intranasal AVP during a socio-emotional eye tracking paradigm and reported effects on both, top-down as well as bottom-up control. Within this context the present study aims to validate the effects of orally administered AVP on top-down and bottom-up attentional control towards socio-affective stimuli. To this end, healthy individuals will undergo a double-blind, between-subjects, placebo-controlled pharmaco-eye-tracking experiment and receive a single oral dose of vasopressin (20 IU) or placebo before performing a saccade/anti-saccade task 45 minutes after administration. The task paradigm will encompass social (happy, angry, fearful, sad and neutral faces) and non-social (oval) stimuli to examine the social and emotion-specific effects of oral vasopressin.
Investigators
Benjamin Becker
Professor
University of Electronic Science and Technology of China
Eligibility Criteria
Inclusion Criteria
- •Healthy subjects who volunteer to participate and are able to fully understand and agree with this study by written informed consent.
- •Normal or corrected-normal version
Exclusion Criteria
- •History of neuropsychiatric diseases.
- •History of cardiac disease, including arrhythmias, aortic stenosis, or congestive heart failure; history of syncope or unexplained loss of consciousness.
- •History of hepatic diseases, including cholestasis, biliary obstructive disease, or severe liver dysfunction.
- •History of renal diseases, including renal stones or renal failure.
- •History of hyponatremia(Serum sodium \<135mmol/L) or hyperkalemia (Serum potassium\>5.5mmol/L); history of diabetes mellitus or diabetes insipidus
- •Known hypersensitivity or allergic reaction to any medication or hormone; strong allergic reaction to food.
- •Infections such as COVID-19 or influenza, or unexplained fever.
- •Subjects with hypertension (BP ≥130/80mmHg) or hypotension (BP ≤ 90/60mmHg).
- •History of alcohol or drug abuse; smoker (≥ 10 cigarettes or ≥ 3 cigars or ≥ 3 pipes/day); smoker using e-cigarettes.
- •Blood donation (≤ 1 month prior to administration).
Arms & Interventions
Placebo group
Placebo
Intervention: Placebo
Vasopressin group
Vasopressin (20IU)
Intervention: Vasopressin
Outcomes
Primary Outcomes
Saccade/antisaccade latency difference between social and non-social stimuli after oral vasopressin administration
Time Frame: 45 minutes - 75 minutes after treatment
Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the vasopressin and placebo treatment conditions.
Error rate of saccade/antisaccade for social versus non-social stimuli after oral vasopressin administration
Time Frame: 45 minutes - 75 minutes after treatment
Comparison between social-specific error rates of saccade/antisaccade between the vasopressin and placebo treatment conditions.
Secondary Outcomes
- Error rate of saccade/antisaccade for different facial emotions after oral vasopressin administration(45 minutes - 75 minutes after treatment)
- Saccade/antisaccade latency for different facial emotions after oral vasopressin administration(45 minutes - 75 minutes after treatment)